

The Effect of Preoperative Anemia on the Outcome After Coronary Surgery

Tuomas Tauriainen¹ · Joni Koski-Vähälä¹ · Eeva-Maija Kinnunen¹ · Fausto Biancari¹

Published online: 13 February 2017
© Société Internationale de Chirurgie 2017

Abstract

Background Preoperative anemia is associated with increased morbidity and mortality after cardiac surgery. Since anemia is ultimately treated with red blood cell transfusions, we investigated the independent impact of anemia and transfusion on the outcome after coronary artery bypass grafting (CABG).

Methods This study included 2761 consecutive patients who underwent isolated CABG. Anemia was defined as hemoglobin <12.0 g/dL in women and <13.0 g/dL in men. The main outcomes were 30-day and late mortality.

Results Patients with preoperative anemia had an increased prevalence of significant comorbidities and were associated with higher unadjusted risk of early and late adverse events. Propensity score matching resulted in 560 pairs with similar baseline and operative characteristics. In these matched pairs, anemic patients had an increased risk of late all-cause death ($P = 0.047$) and acute kidney injury ($P < 0.0001$). However, when adjusted for the severity of perioperative bleeding, preoperative anemia was not associated with an increased mortality risk (HR 1.10, 95% CI 0.86–1.39). Instead, this regression model showed that the European CABG registry (E-CABG) bleeding classification was an independent predictor of late mortality (compared to grade 0: grade 1, HR 1.93, 95% CI 1.37–2.73, grade 2, HR 2.19, 95% CI 1.50–3.18, grade 3, HR 5.59, 95% CI 3.34–9.39, $P < 0.0001$).

Conclusions When adjusted for important baseline characteristics and operative factors as well as for the severity of perioperative bleeding and the amount of transfused blood products, anemia was not associated with an increased risk of adverse events. Increased exposure to blood transfusion among anemic patients may be the determinant of their poorer late survival.

Introduction

Anemia and exposure to red blood cell (RBC) transfusion are predictors of adverse events after cardiac and non-cardiac surgery [1–9]. Differentiating the negative effects of these two factors is difficult since preoperative anemia is itself associated with increased need of RBC transfusions [7, 10–14]. On the other hand, preoperative anemia is relatively common in

patients undergoing cardiac surgery [10] and is a result of multiple causes which, in turn, are risk factors for poor outcome in these patients [15]. The aim of the present study was to evaluate the independent effect of preoperative anemia on the outcome after coronary artery bypass grafting (CABG).

Materials and methods

Patients

The present study includes 2761 consecutive patients who underwent isolated CABG from June 2006 to December 2013 at the Oulu University Hospital, Finland. Complete

✉ Fausto Biancari
faustobiancari@yahoo.it

¹ Department of Surgery, Oulu University Hospital,
P. O. Box 21, 90029 Oulu, Finland

data on pre-, intra- and postoperative variables were available in these patients. Data on the preoperative use of antithrombotics were retrospectively collected. Data on the types and amount of blood products such as RBCs, platelets and solvent/detergent-treated plasma (Octaplas; Octapharma AG, Lachen, Switzerland) were retrieved from a prospective electronic hospital registry. The amount of transfused blood products was estimated from the day of operation until discharge or up to a maximum of 30 days after the operation. Data on the amount of chest drainage output at 12 h after surgery were retrieved from a prospective electronic registry of the intensive care unit. Preoperative anemia was defined a hemoglobin level <12.0 g/dL in women and <13.0 g/dL in men [16]. Clinical variables were defined according to the EuroSCORE II definition criteria [17]. The E-CABG classification of bleeding severity [18] was employed to stratify the severity of perioperative bleeding based on the type and amount of blood products transfused and the need of re sternotomy for excessive bleeding. The E-CABG bleeding grades [18] are: Grade 0, no transfusion of blood products or transfusion of one unit of RBCs; Grade 1, transfusion of platelets, fresh frozen plasma/Octaplas and/or 2–4 units of RBCs; Grade 2, transfusion of 5–10 units of RBCs and/or reoperation for bleeding; Grade 3, transfusion of >10 units of RBCs. Data on patients' death were provided up to January 31, 2016 from the Finnish Population Registry Center, which collects the certificates of death of all inhabitants of Finland. We assume that there are no missing data on any immediate and late death of this study population.

Inclusion criteria

Patients who underwent any elective, urgent or emergency isolated CABG were included in this analysis.

Perioperative antithrombotic treatment

Aspirin was discontinued for 7 days until 2012 and later on was continued until surgery. Warfarin was discontinued for 2 days before surgery. Enoxaparin was used preoperatively only in patients with acute coronary syndrome. Clopidogrel, prasugrel and ticagrelor were discontinued for at least 5 days when feasible.

Heparin (3.0 mg/kg) was administered intraoperatively to maintain an activated coagulation time of longer than 450 s, and it was neutralized at the end of the procedure by protamine sulfate (3.0 mg/kg). Aprotinin was not used in any of these patients. Tranexamic acid was administered intraoperatively at discretion of the anesthesiologist. RBCs were transfused on the operation day if hemoglobin was less than 90 g/L. Later, RBCs were transfused if hemoglobin was less than 80 g/L. Octaplas as well as platelets

were transfused according to the amount of intra- and postoperative bleeding, INR levels and platelet count.

Enoxaparin (40–80 mg once-a-day) was started on the evening of the operation day in those patients without excessive bleeding (<1000 mL). Aspirin 100 mg was restarted on the first postoperative day. Warfarin was restarted on the first postoperative day in patients on chronic oral anticoagulation unless excessive bleeding occurred. Warfarin was started de novo in case of persistent atrial fibrillation. Clopidogrel and ticagrelor were used postoperatively only in case of allergy to aspirin or recent percutaneous coronary intervention.

Operative techniques and management of chest drainages

Intermittent antegrade and retrograde cold blood cardioplegia was used during on-pump CABG. Epiaortic ultrasound was performed according to the surgeon's preference. Octopus stabilizer (Medtronic, Minneapolis, MN) as well as intracoronary shunts were routinely used in patients who underwent off-pump surgery. All blood lost during the operation was collected into a cell saver reservoir and washed. Salvaged red blood cells were transfused during or at the completion of the operation. Mediastinal/pleural blood was collected after surgery in a sterile collection chamber connected to 15 cm H₂O wall suction via an underwater seal and then discarded.

Outcomes

The primary outcomes of this study were 30-day and late mortality. Secondary outcomes were the length of intensive care unit stay, stroke, atrial fibrillation, ventricular fibrillation or asystole, permanent pacemaker implantation, postoperative use of antibiotics, deep sternal wound infection, mediastinitis, low cardiac output syndrome, repeat revascularization, surgery for gastrointestinal complications, acute kidney injury according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria based on peak creatinine level during the in-hospital stay [19], nadir hemoglobin level during the postoperative period and chest drain output 12 h after surgery. Low cardiac output syndrome was defined as postoperative cardiac index <2.0 L/min/m² as measured at least twice. The other outcomes were defined according to the E-CABG definition criteria as previously reported [18].

Statistical analysis

Statistical analysis was performed using SPSS statistical software (version 23.0, IBM Corporation, New York, USA). No attempt to replace missing values was made.

Continuous variables are reported as the mean and standard deviation. Nominal variables are reported as counts and percentages. Fisher's exact test, Chi-square test and Mann–Whitney tests were used for univariate analysis. Risk estimates are reported as beta coefficients, odds ratio (OR) and hazard rate (HR) with 95% confidence interval (95% CI). Observational studies do not provide randomization, and therefore, propensity score matching method was employed to select two groups of patients with and without preoperative anemia having similar baseline and operative characteristics. The propensity score was estimated using a non-parsimonious logistic regression model with the preoperative anemia/non-anemia as the dependent variable. The following variables have been included as covariates: age, gender, body mass index, platelets count, eGFR, dialysis, pulmonary disease, diabetes, stroke, extracardiac arteriopathy, neurological dysfunction, atrial fibrillation, previous percutaneous coronary intervention, previous cardiac surgery, left ventricular ejection fraction $\leq 50\%$, recent myocardial infarction, critical preoperative status, preoperative intra-aortic balloon pump, recent ventricular

arrhythmia, cardiac massage, urgency of the operation, off-pump surgery, epiaortic ultrasound, diseased ascending aorta, bilateral mammary artery grafts and radial artery graft. One-to-one propensity score matching was performed using a caliper width of 0.02 of the standard deviation of the logit of the propensity score. Analysis of the standardized differences after matching was used to assess the balance between the characteristics of propensity-matched pairs. The outcomes of matched groups were evaluated by the *t* test for paired sample for continuous variables and the McNemar test for dichotomous variables. Difference in overall survival at 9 years was evaluated by the Kaplan–Meier method. Logistic regression, linear regression, ordinal regression and Cox proportional hazards analyses of propensity-matched pairs were adjusted for the E-CABG bleeding grades in order to evaluate the impact of blood transfusion and re sternotomy for excessive bleeding on the outcomes. In another regression model, preoperative anemia was adjusted for the number of transfused units of RBCs. All tests were two sided with the alpha level set at 0.05 for statistical significance.

Table 1 Baseline characteristics

Baseline variables	Overall population No. 2761	Overall series			Propensity score matched pairs		
		No preop. anemia No. 2099	Preop. anemia No. 662	<i>P</i> value	No preop. anemia No. 560	Preop. anemia No. 560	<i>P</i> value
Age (years)	66.6 ± 9.1	66.2 ± 9.1	69.9 ± 8.6	<0.0001	69.5 ± 8.7	69.7 ± 8.5	0.566
Females	581 (21.0)	415 (19.8)	166 (25.1)	0.004	130 (23.2)	139 (24.8)	0.529
Body mass index	28.1 ± 4.5	28.3 ± 4.4	27.2 ± 4.6	<0.0001	27.5 ± 4.2	27.4 ± 4.6	0.664
Hemoglobin (g/dL)	13.7 ± 1.6	14.4 ± 1.1	11.5 ± 1.0	<0.0001	14.0 ± 0.9	11.6 ± 1.0	<0.0001
Platelets (109/L)	242 ± 76	240 ± 69	248 ± 94	0.600	247 ± 84.8	248 ± 91	0.983
eGFR (mL/min/1.73 m ²)	86.1 ± 25.2	87.8 ± 22.9	80.5 ± 31.0	<0.0001	82.8 ± 23.9	83.2 ± 27.4	0.359
Pulmonary disease	274 (9.9)	195 (9.3)	79 (11.9)	0.047	59 (10.5)	62 (11.1)	0.773
Diabetes	788 (28.5)	562 (26.8)	226 (34.1)	<0.0001	187 (33.4)	177 (31.6)	0.523
Stroke	95 (3.4)	62 (3.0)	33 (5.0)	0.012	20 (3.6)	24 (4.3)	0.538
Extracardiac arteriopathy	265 (9.6)	168 (8.0)	97 (14.7)	<0.0001	78 (13.9)	69 (12.3)	0.426
Neurological dysfunction	50 (1.8)	36 (1.7)	14 (2.1)	0.501	15 (2.7)	12 (2.1)	0.559
Atrial fibrillation	282 (10.2)	191 (9.1)	91 (13.7)	0.001	63 (11.3)	69 (12.3)	0.578
Previous PCI	199 (7.2)	143 (6.8)	56 (8.5)	0.153	40 (7.1)	41 (7.3)	0.908
Previous cardiac surgery	46 (1.7)	36 (1.7)	10 (1.5)	0.72	6 (1.1)	8 (1.4)	0.591
Left ventricular ejection fraction $\leq 50\%$	697 (26.2)	435 (21.6)	262 (40.7)	<0.0001	213 (38.0)	211 (37.7)	0.902
Recent myocardial infarction	1317 (47.7)	832 (39.6)	485 (73.3)	<0.0001	400 (71.4)	396 (70.7)	0.792
Critical preoperative status	217 (7.9)	99 (4.7)	118 (17.8)	<0.0001	71 (12.7)	81 (14.5)	0.383
Preoperative IABP	11 (0.4)	6 (0.3)	5 (0.8)	0.147	4 (0.7)	3 (0.5)	1.000
Inotropic support	67 (2.4)	25 (1.2)	42 (6.3)	<0.0001	17 (3.0)	22 (3.9)	0.415
Recent ventricular arrhythmia	83 (3.0)	45 (2.1)	38 (5.7)	<0.0001	25 (4.5)	29 (5.2)	0.577
Cardiac massage	43 (1.6)	18 (0.9)	25 (3.8)	<0.0001	14 (2.5)	14 (2.5)	1.000

Continuous variables are reported as mean and standard deviation. Categorical variables are reported as counts and percentages
PCI percutaneous coronary intervention, *IABP* intra-aortic balloon pump, *eGFR* estimated glomerular filtration rate

Results

Baseline and operative data

In this series, 662 patients (24.0%, 22.8% of men and 28.6% of women) had preoperative anemia. Baseline and operative characteristics of these patients are summarized in Tables 1 and 2. The prevalence of comorbidities was significantly higher among anemic patients. In particular, anemic patients were significantly older, had a higher prevalence of recent myocardial infarction and were operated mostly on urgent/emergency basis. Operative factors were similar between the study groups.

Outcomes in the overall series

Outcomes in overall series are summarized in Tables 3 and 4. In-hospital, 30-day and long-term mortalities were significantly increased in patients exposed to anemia ($P < 0.0001$ in all). Unadjusted 8-year survival in non-anemic and anemic patients was 80.2 and 62.4%, respectively.

Preoperative anemia was associated with a significantly increased risk of exposure to blood products (Table 3) and lower nadir hemoglobin values ($P < 0.0001$), whereas blood loss at 12 h was lower (484 ± 416 vs. 509 ± 388 mL, $P = 0.029$) when compared to non-anemic patients.

In univariate analysis, preoperative anemia was associated with significantly longer stay in the intensive care unit, atrial fibrillation, ventricular fibrillation or asystole, post-operative use of antibiotics and acute kidney injury ($P < 0.0001$ in all). The rates of postoperative stroke

($P = 0.001$), low cardiac output syndrome ($P = 0.003$) and surgery for gastrointestinal complications ($P = 0.001$) were also significantly higher among anemic patients.

Propensity score matched analysis

Logistic regression (Hosmer–Lemeshow's test: $P = 0.248$) provided a propensity score with an area under the receiver-operating characteristics curve of 0.773 (95% CI 0.753–0.793). Propensity score matching (caliper width: 0.02) resulted in 560 patient pairs with similar baseline and operative covariates as confirmed by absolute standardized differences $< 10\%$ in all baseline and operative covariates (Fig. 1).

In these propensity-matched pairs, in-hospital (3.0% vs. 3.2%, $P = 1.00$) and 30-day mortality rates (3.9% vs. 3.9%, $P = 1.00$) were similar in non-anemics and anemics. However, Kaplan–Meier analysis showed a better survival among non-anemics at mid-term, but the difference somewhat decreased at long-term follow-up (at 8 years, 68.2% vs. 66.3%, $P = 0.047$, Table 4).

Exposure to RBC transfusion was significantly higher among anemic patients (Table 3). Similarly, nadir hemoglobin level was significantly lower among patients with preoperative anemia (mean 7.6 ± 0.9 vs. 8.3 ± 1.1 g/dL, $P < 0.0001$), but the amount of blood loss at 12 h (mean 477 ± 414 vs. 494 ± 376 mL, $P = 0.408$) and rates of reoperation for bleeding (5.2% vs. 7.1%, $P = 0.222$) were similar between the study groups.

In these propensity score matched pairs, preoperative anemia was associated with a significantly higher rate of acute kidney injury not requiring dialysis (26.3% vs.

Table 2 Operative data

Operative variables	Overall population No. 2761	Overall series			Propensity score matched pairs		
		No preop. anemia No. 2099	Preop. anemia No. 662	<i>P</i> value	No preop. anemia No. 560	Preop. anemia No. 560	<i>P</i> value
Urgency status				< 0.0001			0.950
Elective	1259 (45.6)	1125 (53.6)	134 (20.2)		124 (22.1)	127 (22.7)	
Urgent	1306 (47.3)	869 (41.4)	437 (66.0)		375 (67.0)	370 (66.1)	
Emergency	196 (7.1)	105 (5.0)	91 (13.7)		61 (10.9)	63 (11.3)	
Off-pump surgery	1507 (54.6)	1137 (54.2)	370 (55.9)	0.438	315 (56.3)	309 (55.2)	0.718
Epi-aortic ultrasound	1448 (52.4)	1097 (52.3)	351 (53.0)	0.733	311 (55.5)	296 (52.9)	0.368
Diseased ascending aorta	225 (8.1)	161 (7.7)	64 (9.7)	0.101	50 (8.9)	53 (9.5)	0.756
Number of distal anastomoses	4.0 ± 1.1	4.0 ± 1.1	3.9 ± 1.1	0.510	4.0 ± 1.0	3.9 ± 1.0	0.977
Length of the operation (min)	249 ± 69	249 ± 71	246 ± 62	0.324	248 ± 54	244 ± 56	0.569

Continuous variables are reported as mean and standard deviation. Categorical variables are reported as counts and percentages
CPB cardiopulmonary bypass

Table 3 Bleeding-related outcomes

	Overall population No. 2761	Overall series			Propensity score matched pairs		
		No preop. anemia No. 2099	Preop. anemia No. 662	<i>P</i> value	No preop. anemia No. 560	Preop. anemia No. 560	<i>P</i> value
Nadir hemoglobin (g/dL)	8.3 ± 1.2	8.5 ± 1.2	7.6 ± 0.9	<0.0001	8.3 ± 1.1	7.6 ± 0.9	<0.0001
Blood loss at 12 h (mL)	504 ± 394	509 ± 388	484 ± 416	0.029	494 ± 376	477 ± 414	0.408
RBC transfusion	1753 (63.5)	1160 (55.3)	593 (89.6)	<0.0001	393 (70.2)	497 (88.8)	<0.0001
RBC units transfused	2.5 ± 3.4	1.9 ± 2.8	4.5 ± 4.2	<0.0001	2.7 ± 3.7	3.9 ± 3.5	<0.0001
Octaplas transfusion	737 (26.7)	514 (24.5)	223 (33.7)	<0.0001	174 (31.1)	175 (31.3)	1.000
Octaplas units transfused	1.2 ± 2.4	1.0 ± 2.1	1.7 ± 3.3	<0.0001	1.3 ± 2.4	1.3 ± 2.6	0.546
Platelet transfusion	824 (29.8)	562 (26.8)	262 (39.6)	<0.0001	192 (34.3)	202 (36.1)	0.568
Platelet units transfused	3.0 ± 6.1	2.5 ± 5.0	4.5 ± 8.6	<0.0001	3.4 ± 6.1	3.4 ± 6.1	0.178
Resternotomy for bleeding	180 (6.5)	139 (6.6)	41 (6.2)	0.697	40 (7.1)	29 (5.2)	0.222
Procedure of retained blood within 30 days	253 (9.2)	191 (9.1)	62 (9.4)	0.836	58 (10.4)	45 (8.0)	0.198
E-CABG bleeding grades				0.001			<0.0001
Grade 1	1116 (40.4)	819 (39.0)	297 (44.9)		257 (45.9)	259 (46.3)	
Grade 2	504 (18.3)	283 (13.5)	221 (33.4)		101 (18.0)	183 (32.7)	
Grade 3	68 (2.5)	27 (1.3)	41 (6.2)		15 (2.7)	25 (4.5)	

Continuous variables are reported as mean and standard deviation. Categorical variables are reported as counts and percentages
RBC red blood cell

15.9%, $P < 0.0001$), without any increased risk of other early adverse events.

In view of the increased need of RBC transfusion among patients with preoperative anemia (Table 3), analyses in these propensity score matched pairs were further adjusted for the severity of perioperative bleeding/amount of transfusion as stratified by the E-CABG bleeding classification. These adjusted analyses showed that preoperative anemia was associated only with an increased risk of acute kidney injury not requiring dialysis (OR 1.50, 95% CI 1.10–2.03), whereas other early outcomes were similar between anemics and non-anemics (Table 3).

Cox proportional hazards model in propensity-matched pairs including preoperative anemia and the severity of preoperative bleeding stratified by the E-CABG bleeding classification showed that anemia (HR 1.10, 95% CI 0.86–1.39, Fig. 2) was not an independent predictor of late death. Instead, this regression model showed that the E-CABG bleeding classification was an independent predictor of mortality (compared to grade 0: grade 1, HR 1.93, 95% CI 1.37–2.73, grade 2, HR 2.19, 95% CI 1.50–3.18, grade 3, HR 5.59, 95% CI 3.34–9.39, $P < 0.0001$). Similarly, anemia adjusted for the amount of transfused units of RBCs was not associated with poorer survival (HR 1.16, 95% CI 0.91–1.47), whereas the number of transfused RBCs was associated with increased risk of late death (per RBC unit: RR 1.06, 95% CI 1.04–1.08).

Discussion

The main finding of this study is that preoperative anemia is not associated with poorer survival when adjusted for baseline covariates and severity of perioperative bleeding.

Several studies showed that RBC transfusion is associated with increased mortality and morbidity after cardiac surgery [8, 20, 21]. In turn, anemic patients are more likely to receive transfusions [7, 10–14] and preoperative anemia itself has been shown to be a risk factor for adverse events [4, 22–24]. However, the interaction between the anemia status and the increased need of transfusion makes difficult to disentangle the individual prognostic impact of these two factors. In their seminal contribution, Loor et al. [1] demonstrated the independent role of anemia and transfusion on the outcomes after cardiac surgery and concluded that both may have a significant and independent impact on adverse events. However, anemia and transfusion were assessed only intraoperatively, and this prevented conclusive results on this issue. Indeed, using a different methodology and evaluating anemia, blood loss and transfusion during the entire postoperative period, preoperative anemia was not a risk factor for late mortality in propensity score matched pairs adjusted for exposure to blood products. The only adverse event associated with preoperative anemia was an increased risk of acute kidney injury. These findings were observed although preoperative anemia was associated with significantly lower nadir

Table 4 Outcomes in the overall series and in propensity score matched cohorts

	Overall population No. 2761		Overall series		Propensity score matched pairs		Adjusted analysis risk estimate (95% CI)
	No. 2099	Preop. anemia No. 662	No preop. anemia No. 2099	Preop. anemia No. 662	No preop. anemia No. 560	Preop. anemia No. 560	
In-hospital death	66 (2.4)	28 (4.2)	38 (1.8)	28 (4.2)	18 (3.2)	17 (3.0)	0.61, 0.31 to 1.23
30-day mortality	89 (3.2)	41 (6.2)	48 (2.3)	41 (6.2)	22 (3.9)	22 (3.9)	0.67, 0.36 to 1.26
ICU stay (days)	2.2 ± 2.5	2.9 ± 3.5	1.9 ± 2.0	2.9 ± 3.5	2.4 ± 2.6	2.6 ± 3.1	-0.29, -0.62 to 0.04
Stroke	58 (2.1)	25 (3.8)	33 (1.6)	25 (3.8)	14 (2.5)	17 (3.0)	0.93, 0.45 to 1.93
Atrial fibrillation	1185 (42.9)	337 (50.9)	848 (40.4)	337 (50.9)	276 (49.3)	278 (49.6)	0.95, 0.74 to 1.20
Ventricular fibrillation/asystole	48 (1.7)	24 (3.6)	24 (1.1)	24 (3.6)	11 (2.0)	18 (3.2)	1.13, 0.52 to 2.47
Permanent pace-maker implantation	18 (0.7)	7 (1.1)	11 (0.5)	7 (1.1)	4 (0.7)	6 (1.1)	1.39, 0.38 to 5.12
Low cardiac output syndrome	382 (13.8)	115 (17.4)	267 (12.7)	115 (17.4)	95 (17.0)	92 (16.4)	0.78, 0.54 to 1.05
Postop. intra-aortic balloon pump	16 (0.6)	5 (0.8)	11 (0.5)	5 (0.8)	6 (1.1)	4 (0.7)	0.46, 0.13 to 1.68
Repeat CABG or PCI	14 (0.5)	4 (0.6)	10 (0.5)	4 (0.6)	1 (0.2)	3 (0.5)	1.67, 0.17 to 16.24
Post-operative use of antibiotics	935 (33.9)	322 (48.6)	613 (29.2)	322 (48.6)	211 (37.7)	258 (46.1)	1.17, 0.91 to 1.50
Deep sternal wound infection	40 (1.4)	14 (2.1)	26 (1.2)	14 (2.1)	7 (1.3)	10 (1.8)	1.24, 0.46 to 3.35
Mediastinitis	43 (1.6)	14 (2.1)	29 (1.4)	14 (2.1)	10 (1.8)	10 (1.8)	0.88, 0.35 to 2.18
Surgery for gastrointestinal. compl.	32 (1.2)	16 (2.4)	16 (0.8)	16 (2.4)	6 (1.1)	10 (1.8)	1.03, 0.36 to 2.95
Acute kidney injury							-0.31, -0.60 to -0.01
Grade 1	325 (12.0)	144 (23.0)	181 (8.7)	144 (23.0)	71 (12.9)	124 (22.4)	
Grade 2	71 (2.6)	31 (4.9)	40 (1.9)	31 (4.9)	17 (3.1)	25 (4.5)	
Grade 3	61 (2.3)	28 (4.5)	33 (1.6)	28 (4.5)	17 (3.1)	21 (3.8)	
New renal replacement therapy	51 (1.9)	23 (3.6)	28 (1.3)	23 (3.6)	16 (2.9)	17 (3.0)	0.61, 0.29 to 1.29
Acute kidney injury without dialysis	396 (14.3)	173 (26.1)	223 (10.6)	173 (26.1)	89 (15.9)	147 (26.3)	1.50, 1.10 to 2.03
Survival ^a							
1-year		88.7% (587)	96.0% (2015)	88.7% (587)	92.9% (520)	92.0% (515)	
5-year		72.7% (319)	88.4% (1287)	72.7% (319)	82.9% (315)	76.9% (280)	
8-year		62.4% (82)	80.2% (471)	62.4% (82)	68.2% (104)	66.3% (72)	

Continuous variables are reported as mean and standard deviation. Categorical variables are reported as counts and percentages. Risk estimates in bold indicate statistical significance in multivariate analysis

ICU intensive care unit, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, risk estimates are odds ratio or beta coefficient, 95% CI 95% confidence interval

^a Parentheses are patients at risk




Fig. 1 Absolute standardized difference before and after propensity score matching in the cohorts of patients with and without anemia


hemoglobin levels without a difference in the amount of postoperative blood loss. However, some investigators consider anemia as a risk factor for increased bleeding because of its possible associated coagulopathy [25, 26].

Since preoperative anemia is a modifiable condition, the hypothetical possibility to reverse its related risk of adverse events is intriguing. Evidence from previous studies suggests that the prevalence of preoperative anemia might be higher in cardiac surgery [4, 5, 10, 22], than in the general population of similar age, from developed countries [27–29]. Increased comorbidities among patients requiring revascularization might explain the difference. Older age [22], lower baseline eGFR [19] and poor left ventricular

ejection fraction [30] are associated with higher incidence of anemia. In addition to these factors, the present study identified recent myocardial infarction and critical preoperative status as significantly associated with preoperative anemia. We speculate that lower hemoglobin values observed in these two patient groups might be due, in some patients with critical conditions, to hemodilutional anemia secondary to substantial preoperative infusion of fluids.

However, the potential benefits of preoperative hemoglobin optimization are still unclear. Recent studies on the issue reported promising results. Preoperative treatment with EPO and/or intravenous iron is considered reasonable [31, 32] and shown to reduce the need for RBC transfusion

Fig. 2 Cox proportional hazards estimate of survival in patients with and without anemia as adjusted by the E-CABG bleeding severity classification (HR, 1.10, 95% CI 0.86–1.39)



[33–35]. Hemoglobin optimization > 12 g/dL was observed to improve the outcomes of Jehovah’s witnesses undergoing cardiac surgery [36].

Our study has some limitations which should be acknowledged. First, data collection was performed retrospectively. However, data on the amount of blood loss and use of blood products were recorded prospectively. This makes the estimation of perioperative bleeding and exposure to blood products rather reliable. Second, analysis limited to patients undergoing elective CABG would have enabled the exclusion of the impact of potential preoperative hemodilutional anemia, but it would have reduced the statistical power of this analysis. Importantly, propensity score matching provided pairs with similar prevalence of risk factors for critical prognostic importance. Third, this study does not address the possible multiple causes underlying preoperative anemia, and some of them might have a prognostic impact which is left unrecognized. The strengths of the study are a relatively large database and a long follow-up with complete survival data.

Conclusions

In this study, preoperative anemia in patients undergoing CABG was associated with significant baseline comorbidities. When adjusted for important baseline characteristics and operative factors as well as for the severity of perioperative bleeding and the amount of transfused blood products, anemia was not associated with increased risk of adverse events. Increased exposure to blood transfusion

among anemic patients may be the determinant of their poorer late survival.

Compliance with ethical standards

Conflict of interest None.

Ethical approval This study was approved by the Institutional Review Board of the Oulu University Hospital.

References

1. Loor G, Rajeswaran J, Li L et al (2013) The least of 3 evils: exposure to red blood cell transfusion, anemia, or both? *J Thorac Cardiovasc Surg* 146:1480–1487
2. Ranucci M, Baryshnikova E, Castelvechio S, Surgical and Clinical Outcome Research (SCORE) Group et al (2013) Major bleeding, transfusions, and anemia: the deadly triad of cardiac surgery. *Ann Thorac Surg* 96:478–485
3. von Heymann C, Kaufner L, Sander M, et al (2016) Does the severity of preoperative anemia or blood transfusion have a stronger impact on long-term survival after cardiac surgery? *J Thorac Cardiovasc Surg* 152:1412–1420
4. Karkouti K, Wijeyesundera DN, Beattie WS, Reducing Bleeding in Cardiac Surgery (RBC) Investigators (2008) Risk associated with preoperative anemia in cardiac surgery: a multicenter cohort study. *Circulation* 117:478–484
5. Kulier A, Levin J, Moser R, Investigators of the Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation et al (2007) Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. *Circulation* 116:471–479
6. Spiegelstein D, Holmes SD, Pritchard G et al (2015) Preoperative hematocrit as a predictor of perioperative morbidities following nonemergent coronary artery bypass surgery. *J Card Surg* 30:20–26

7. Musallam KM, Tamim HM, Richards T et al (2011) Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. *Lancet* 378:1396–1407
8. Oliver E, Carrio ML, Rodriguez-Castro D et al (2009) Relationships among haemoglobin level, packed red cell transfusion and clinical outcomes in patients after cardiac surgery. *Intensive Care Med* 35:1548–1555
9. Richards T, Musallam KM, Nassif J et al (2015) Impact of pre-operative anaemia and blood transfusion on postoperative outcomes in gynaecological surgery. *PLoS ONE* 10:e0130861
10. Hung M, Besser M, Sharples LD et al (2011) The prevalence and association with transfusion, intensive care unit stay and mortality of pre-operative anaemia in a cohort of cardiac surgery patients. *Anaesthesia* 66:812–818
11. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, Saha SP et al (2007) Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists clinical practice guideline. *Ann Thorac Surg* 83:S27–S86
12. Ranucci M, Di Dedda U, Castelvechio S, Surgical and Clinical Outcome Research (SCORE) Group et al (2012) Impact of pre-operative anemia on outcome in adult cardiac surgery: a propensity-matched analysis. *Ann Thorac Surg* 94:1134–1141
13. Matsuda S, Fukui T, Shimizu J et al (2013) Associations between preoperative anemia and outcomes after off-pump coronary artery bypass grafting. *Ann Thorac Surg* 95:854–860
14. Kim CJ, Connell H, McGeorge AD et al (2015) Prevalence of preoperative anaemia in patients having first-time cardiac surgery and its impact on clinical outcome. A retrospective observational study. *Perfusion* 30:277–283
15. Patel KV (2008) Epidemiology of anemia in older adults. *Semin Hematol* 45:210–217
16. World Health Organization, Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. In: World Health Organization. Vitamin and Mineral Nutrition Information System (VMNIS). 2011, WHO/NMH/NHD/MNM/11.1. <http://www.who.int/vmnis/indicators/haemoglobin.pdf>. Accessed 21 July 2016
17. Nashef SA, Roques F, Sharples LD et al (2012) EuroSCORE II. *Eur J Cardiothorac Surg* 41:734–744
18. Biancari F, Ruggieri VG, Perrotti A et al (2015) European multicenter study on coronary artery bypass grafting (E-CABG registry): study protocol for a prospective clinical registry and proposal of classification of postoperative complications. *J Cardiothorac Surg* 10:90
19. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Inter Suppl* 3:1–150
20. Shaw RE, Johnson CK, Ferrari G et al (2013) Balancing the benefits and risks of blood transfusions in patients undergoing cardiac surgery: a propensity-matched analysis. *Interact Cardiovasc Thorac Surg* 17:96–102
21. Scott BH, Seifert FC, Grimson R (2008) Blood transfusion is associated with increased resource utilisation, morbidity and mortality in cardiac surgery. *Ann Card Anaesth* 11:15–19
22. Miceli A, Romeo F, Glauber M et al (2014) Preoperative anemia increases mortality and postoperative morbidity after cardiac surgery. *J Cardiothorac Surg* 9:137
23. Klein AA, Collier TJ, Brar MS, Association of Cardiothoracic Anaesthetists (ACTA) et al (2016) The incidence and importance of anaemia in patients undergoing cardiac surgery in the UK—the first association of cardiothoracic anaesthetists national audit. *Anaesthesia* 71:627–635
24. Fowler AJ, Ahmad T, Phull MK et al (2015) Meta-analysis of the association between preoperative anaemia and mortality after surgery. *Br J Surg* 102:1314–1324
25. Valeri CR, Cassidy G, Pivacek LE et al (2001) Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. *Transfusion* 41:977–983
26. Ho CH (1998) The hemostatic effect of packed red cell transfusion in patients with anemia. *Transfusion* 38:1011–1014
27. Tettamanti M, Lucca U, Gandini F et al (2010) Prevalence, incidence and types of mild anemia in the elderly: the “Health and Anemia” population-based study. *Haematologica* 95:1849–1856
28. Martinsson A, Andersson C, Andell P et al (2014) Anemia in the general population: prevalence, clinical correlates and prognostic impact. *Eur J Epidemiol* 29:489–498
29. World Health Organization, (2008) World wide prevalence of anaemia 1993-2005, WHO global database on anaemia. http://whqlibdoc.who.int/publications/2008/9789241596657_eng.pdf?ua=1. Accessed 12 Sept 2016
30. Nijst P, Verbrugge FH, Bertrand PB et al (2016) Plasma volume is normal but heterogeneously distributed and true anemia is highly prevalent in patients with stable heart failure. *J Card Fail* 23:138–144
31. American society of anesthesiologists task force on perioperative blood management (2015) Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. *Anesthesiology* 122:241–275
32. Society of thoracic surgeons blood conservation guideline task force, Ferraris VA, Brown JR et al (2011) 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines. *Ann Thorac Surg* 91:944–948
33. Cladellas M, Farre N, Comin-Colet J et al (2012) Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement. *Am J Cardiol* 110:1021–1026
34. Sowade O, Warnke H, Scigalla P et al (1997) Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. *Blood* 89:411–418
35. Litton E, Xiao J, Ho KM (2013) Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomized clinical trials. *BMJ* 347:f4822
36. Tanaka A, Ota T, Uriel N et al (2015) Cardiovascular surgery in Jehovah’s witness patients: the role of preoperative optimization. *J Thorac Cardiovasc Surg* 150:976–983